Samsung Biologics offered 1.46 billion Swiss francs, about 1.8 billion dollars, in cash on Monday for PolyPeptide Group, a Swiss company that manufactures peptides for other drugmakers. If the deal closes, it will be the largest biopharmaceutical acquisition in South Korean history.
The terms are a straight cash buyout. Samsung is paying 44.31 Swiss francs (about 54.80 dollars) per share, a 40 percent premium over the price PolyPeptide traded at before the offer became public, according to BioSpace ↗. PolyPeptide's board recommended the offer unanimously, and its largest shareholder has committed roughly 55.65 percent of the shares, per Samsung's own announcement ↗. That leaves only a small gap to the two-thirds acceptance the offer needs to complete, which Samsung expects to reach by the end of 2026.
Why an antibody company is buying a peptide plant
Samsung Biologics is a contract manufacturer. Drugmakers hire it to produce their medicines instead of building factories of their own. Until now its business was almost entirely antibodies, large proteins grown inside living cells. Peptides are made a different way. They are short chains of amino acids assembled chemically, one building block at a time, through a process called solid-phase peptide synthesis, and they need dedicated equipment and know-how that a cell-culture plant does not have.
Buying PolyPeptide buys that capability whole, along with its plants in the United States, Europe, and India. Samsung framed the move as a step toward multi-modality, meaning it wants to make more than one class of drug rather than antibodies alone.
The thing driving the price is obesity
Peptide demand is high right now for one reason. The biggest obesity and diabetes drugs are peptides. Semaglutide ↗, sold as Ozempic and Wegovy, and tirzepatide ↗, sold as Mounjaro and Zepbound, are both chemically synthesized peptides that act on the GLP-1 receptor ↗. Every dose has to be manufactured, and the companies that make them have been running short of capacity. A peptide contract shop with proven output is a scarce asset, which is roughly what a 40 percent premium says out loud.
There is a countercurrent worth naming. The newest weight-loss drugs are oral small molecules, not peptides, and they skip peptide synthesis entirely. Lilly's orforglipron is the first of that class on the market. Samsung is betting that injectable peptide demand stays large enough, for long enough, to earn back 1.8 billion dollars even as the pills arrive. The obesity market is big enough that both things can be true at once.
What to watch now is the acceptance threshold. The offer needs two-thirds of shares tendered to close, and with 55.65 percent already committed, the open question is whether the rest follow the board before the year runs out.